英国制药巨头葛兰素史克计划以最高20亿美元现金,收购波士顿制药公司旗下子公司BP Asset IX。此次交易旨在扩充其药物管线,聚焦创新疗法领域。具体条款尚未披露,但预计将进一步增强葛兰素史克在全球医药市场的竞争力。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.